S&P 500   4,355.90 (-1.96%)
DOW   34,317.97 (-1.58%)
QQQ   360.85 (-2.57%)
AAPL   142.42 (-2.03%)
MSFT   284.90 (-3.15%)
FB   341.68 (-3.37%)
GOOGL   2,725.60 (-3.40%)
TSLA   781.36 (-1.26%)
AMZN   3,315.13 (-2.66%)
NVDA   207.90 (-4.02%)
BABA   152.20 (+1.35%)
NIO   35.26 (-4.11%)
CGC   14.18 (-3.60%)
GE   105.96 (+0.58%)
MU   73.64 (-2.05%)
AMD   102.08 (-5.62%)
T   27.29 (-0.40%)
F   14.36 (+1.41%)
ACB   6.84 (+7.04%)
DIS   174.58 (-2.06%)
PFE   43.17 (-0.92%)
BA   219.34 (-2.15%)
AMC   37.50 (-4.58%)
S&P 500   4,355.90 (-1.96%)
DOW   34,317.97 (-1.58%)
QQQ   360.85 (-2.57%)
AAPL   142.42 (-2.03%)
MSFT   284.90 (-3.15%)
FB   341.68 (-3.37%)
GOOGL   2,725.60 (-3.40%)
TSLA   781.36 (-1.26%)
AMZN   3,315.13 (-2.66%)
NVDA   207.90 (-4.02%)
BABA   152.20 (+1.35%)
NIO   35.26 (-4.11%)
CGC   14.18 (-3.60%)
GE   105.96 (+0.58%)
MU   73.64 (-2.05%)
AMD   102.08 (-5.62%)
T   27.29 (-0.40%)
F   14.36 (+1.41%)
ACB   6.84 (+7.04%)
DIS   174.58 (-2.06%)
PFE   43.17 (-0.92%)
BA   219.34 (-2.15%)
AMC   37.50 (-4.58%)
S&P 500   4,355.90 (-1.96%)
DOW   34,317.97 (-1.58%)
QQQ   360.85 (-2.57%)
AAPL   142.42 (-2.03%)
MSFT   284.90 (-3.15%)
FB   341.68 (-3.37%)
GOOGL   2,725.60 (-3.40%)
TSLA   781.36 (-1.26%)
AMZN   3,315.13 (-2.66%)
NVDA   207.90 (-4.02%)
BABA   152.20 (+1.35%)
NIO   35.26 (-4.11%)
CGC   14.18 (-3.60%)
GE   105.96 (+0.58%)
MU   73.64 (-2.05%)
AMD   102.08 (-5.62%)
T   27.29 (-0.40%)
F   14.36 (+1.41%)
ACB   6.84 (+7.04%)
DIS   174.58 (-2.06%)
PFE   43.17 (-0.92%)
BA   219.34 (-2.15%)
AMC   37.50 (-4.58%)
S&P 500   4,355.90 (-1.96%)
DOW   34,317.97 (-1.58%)
QQQ   360.85 (-2.57%)
AAPL   142.42 (-2.03%)
MSFT   284.90 (-3.15%)
FB   341.68 (-3.37%)
GOOGL   2,725.60 (-3.40%)
TSLA   781.36 (-1.26%)
AMZN   3,315.13 (-2.66%)
NVDA   207.90 (-4.02%)
BABA   152.20 (+1.35%)
NIO   35.26 (-4.11%)
CGC   14.18 (-3.60%)
GE   105.96 (+0.58%)
MU   73.64 (-2.05%)
AMD   102.08 (-5.62%)
T   27.29 (-0.40%)
F   14.36 (+1.41%)
ACB   6.84 (+7.04%)
DIS   174.58 (-2.06%)
PFE   43.17 (-0.92%)
BA   219.34 (-2.15%)
AMC   37.50 (-4.58%)
NASDAQ:OGI

OrganiGram Stock Forecast, Price & News

$2.39
-0.07 (-2.85 %)
(As of 09/28/2021 03:33 PM ET)
Add
Compare
Today's Range
$2.37
$2.49
50-Day Range
$2.32
$2.90
52-Week Range
$1.01
$6.45
Volume158,732 shs
Average Volume13.10 million shs
Market Capitalization$716.56 million
P/E RatioN/A
Dividend YieldN/A
Beta0.1
30 days | 90 days | 365 days | Advanced Chart
Receive OGI News and Ratings via Email

Sign-up to receive the latest news and ratings for OrganiGram and its competitors with MarketBeat's FREE daily newsletter.


OrganiGram logo

About OrganiGram

OrganiGram Holdings, Inc. engages in the production and sale of medical marijuana. It focuses on producing cannabis for patients and adult recreational consumers. The firm's brands include Adult Recreational and Medical. The company was founded on July 5, 2010 and is headquartered in Moncton, Canada.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OGI
CIK
N/A
Employees
517
Year Founded
N/A

Sales & Book Value

Annual Sales
$64.61 million
Cash Flow
$0.02 per share
Book Value
$1.15 per share

Profitability

Net Income
$-101,290,000.00
Net Margins
-190.24%

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$716.56 million
Next Earnings Date
11/29/2021 (Estimated)
Optionable
Not Optionable

MarketRank

Overall MarketRank

1.71 out of 5 stars

Medical Sector

863rd out of 1,353 stocks

Pharmaceutical Preparations Industry

423rd out of 666 stocks

Analyst Opinion: 3.1Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -












OrganiGram (NASDAQ:OGI) Frequently Asked Questions

Is OrganiGram a buy right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OrganiGram in the last twelve months. There are currently 6 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" OrganiGram stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OGI, but not buy additional shares or sell existing shares.
View analyst ratings for OrganiGram
or view top-rated stocks.

What stocks does MarketBeat like better than OrganiGram?

Wall Street analysts have given OrganiGram a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but OrganiGram wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is OrganiGram's next earnings date?

OrganiGram is scheduled to release its next quarterly earnings announcement on Monday, November 29th 2021.
View our earnings forecast for OrganiGram
.

How were OrganiGram's earnings last quarter?

OrganiGram Holdings Inc. (NASDAQ:OGI) released its quarterly earnings data on Monday, July, 12th. The company reported ($0.01) EPS for the quarter, beating analysts' consensus estimates of ($0.03) by $0.02. The company earned $16.55 million during the quarter, compared to analyst estimates of $13.95 million. OrganiGram had a negative net margin of 190.24% and a negative trailing twelve-month return on equity of 19.91%.
View OrganiGram's earnings history
.

How has OrganiGram's stock price been impacted by COVID-19 (Coronavirus)?

OrganiGram's stock was trading at $1.72 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, OGI shares have increased by 39.0% and is now trading at $2.39.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for OGI?

8 analysts have issued twelve-month price targets for OrganiGram's stock. Their forecasts range from $3.50 to $6.00. On average, they anticipate OrganiGram's share price to reach $4.21 in the next year. This suggests a possible upside of 76.3% from the stock's current price.
View analysts' price targets for OrganiGram
or view top-rated stocks among Wall Street analysts.

Who are OrganiGram's key executives?

OrganiGram's management team includes the following people:
  • Beena G. Goldenberg, Chief Executive Officer
  • Derrick W. West, Chief Financial Officer
  • Paolo de Luca, Chief Strategy Officer
  • Borna Zlamalik, Vice President-Innovation
  • Tim Emberg, Senior VP-Sales & Commercial Operations

What other stocks do shareholders of OrganiGram own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OrganiGram investors own include KushCo (KSHB), (CGC), Auxly Cannabis Group (CBWTF), The Supreme Cannabis (SPRWF), Medical Marijuana (MJNA), Cannabics Pharmaceuticals (CNBX), MariMed (MRMD), Aurora Cannabis (ACB), EVIO (EVIO) and Gran Tierra Energy (GTE).

What is OrganiGram's stock symbol?

OrganiGram trades on the NASDAQ under the ticker symbol "OGI."

Who are OrganiGram's major shareholders?

OrganiGram's stock is owned by a variety of retail and institutional investors. Top institutional investors include Susquehanna International Group LLP (0.00%), Penserra Capital Management LLC (0.30%), Morgan Stanley (0.29%), Morgan Stanley (0.28%), Bank of Montreal Can (0.27%) and Millennium Management LLC (0.21%).

Which institutional investors are selling OrganiGram stock?

OGI stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, CIBC World Markets Inc., Penserra Capital Management LLC, Squarepoint Ops LLC, Renaissance Technologies LLC, IMC Chicago LLC, Goldman Sachs Group Inc., and Bank of America Corp DE.

Which institutional investors are buying OrganiGram stock?

OGI stock was acquired by a variety of institutional investors in the last quarter, including Jump Financial LLC, Deutsche Bank AG, Morgan Stanley, Morgan Stanley, Bank of Montreal Can, Group One Trading L.P., BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp, and Susquehanna International Group LLP.

How do I buy shares of OrganiGram?

Shares of OGI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OrganiGram's stock price today?

One share of OGI stock can currently be purchased for approximately $2.39.

How much money does OrganiGram make?

OrganiGram has a market capitalization of $716.56 million and generates $64.61 million in revenue each year. The company earns $-101,290,000.00 in net income (profit) each year or ($0.08) on an earnings per share basis.

How many employees does OrganiGram have?

OrganiGram employs 517 workers across the globe.

What is OrganiGram's official website?

The official website for OrganiGram is www.organigram.ca.

Where are OrganiGram's headquarters?

OrganiGram is headquartered at 35 English Dr., Moncton Z4, E1E 3X3.

How can I contact OrganiGram?

OrganiGram's mailing address is 35 English Dr., Moncton Z4, E1E 3X3. The company can be reached via phone at (844) 644-4726.


This page was last updated on 9/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.